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Introduction. Incidence of Coccidioidomycosis has been increasing nationally, from 
2,271 cases in 1998 to 17,802 cases in 2012. Missouri is not endemic to 
Coccidioidomycosis but the incidence has been increasing since becoming reportable in 
2003. To describe epidemiology of Coccidioidomycosis in Missouri we conducted a 
retrospective review of surveillance data at Missouri Department of Health & Senior 
Services (DHSS) for the years, 2004-2013. 
 
Methods. Data was obtained from Missouri Health Surveillance Information System 
(WebSurv), the statewide reporting system for notifiable diseases. All cases that were 
“Confirmed” were included in the study. 
 
Results. There were a total of 93 confirmed cases eligible for the study, of which 67 
(72%) were male and 26 (28%) were female. The incidence rate of Coccidioidomycosis 
increased from 0.05 per 100,000 population in 2004 to 0.28 per 100,000 in 2013. The age 
groups, > 70 yrs (24%) and  60-69 years (23%) were most affected. The predominant 




Pneumonia (23%) and Flu-like illness (22%) were the most common presentations. 
Culture (26%) and Complement Fixation (20%) were the most common diagnostic tests. 
Median time from symptom onset to diagnosis was 25 days (range 3 – 304 days). A total 
of 43 (46%) patients required hospitalization and 5 of these were admitted to an ICU. Of 
the 69 patients with known travel history, 45 had history of travel to endemic regions and 
24 had no travel history. Mapping of cases with and without history of travel to the 
endemic areas outside the state revealed that cases were occurring in all regions of 
Missouri. Those with history of travel were significantly more likely to be diagnosed 
based on positive culture and/or PCR testing compared to those who did not travel, who 
were more likely to be diagnosed with serological tests.  
 
Conclusions. Our study demonstrated significant increase in the incidence of 
Coccidioidomycosis in Missouri during 2004-2013. Majority of cases were related to 
travel to endemic areas. There was a similar distribution of cases with or without travel to 
endemic areas across the state. Additional studies will be required to ascertain whether 






CHAPTER 1. INTRODUCTION 
 
AGENT 
Coccidioidomycosis, or Valley Fever, is a systemic disease caused by the fungus 
Coccidioides, which is endemic to southwestern region of the United States, Mexico, 
Central and South America (Figure 1).1  This fungus normally resides in the soil and 
people get infected through the inhalation of airborne spores. Coccidioides genetically 
comprises of two species, C immitis, which is limited to the San Joaquin Valley of 
California, and C posadasii, which is found throughout the rest of the endemic areas.2 
However, despite the genetic speciation, there is minimal to no difference in their 
morphology and no clinical or immunologic difference in the infection caused by either 
species.3 
 









Figure 2. Life cycle of Coccidioides 
 
The fungus grows in the soil as mold and reproduces asexually by forming arthroconidia 
(spores) from the hyphae that disperse into the atmosphere by wind in dry conditions. 
Infection in humans and animals occurs through inhalation of the dust-borne spores. In 
the lungs, the spores change into spherules, which then form multiple endospores 
(progeny) inside. Once the spherule ruptures, endospores are released and each is capable 







Exposure to infected dust is the main risk factor for acquiring infection; human-to-human 
transmission is extremely rare.1 In the United States, the endemic areas for 
Coccidioidomycosis are California, Arizona, Nevada, Utah, New Mexico and Texas.5 It 
is notifiable nationally and is reportable to the CDC in the following states: Arizona, 
California, Delaware, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, 
Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Ohio, Rhode Island, 
Utah, Washington, and Wyoming.6 Coccidioidomycosis is endemic but not reportable in 
Texas. The majority of cases occur in Arizona and California. During the years, 1998-
2011, the total reported cases to the CDC from 28 states and the District of Columbia 
were 111,717 and of these 66% were from Arizona, 31% from California, 1% from rest 
of the endemic states, and less than 1% from non-endemic states.7 
 
The number of reported cases of Coccidioidomycosis in the United States has been 
increasing over the past several years. In the endemic areas (excluding Texas), the age-
adjusted incidence rose from 5.3 cases per 100,000 population in 1998 to 42.6 per 
100,000 in 2011.7. There were 240 cases reported in 2011 in non-endemic areas 
compared with 6 cases in 1998.6 Missouri is not considered an endemic state for 
Coccidioidomycosis, but it became a reportable condition in 2003, and since then the rate 








An estimated 150,000 new infections occur annually in the United States.9 Of these, 60% 
are asymptomatic and do not come to medical attention.10 Symptomatic individuals 
develop a flu-like illness—fever, headache, cough, sore throat, night sweats, body aches, 
dyspnea, and pleuritic chest pain—approximately 7 to 21 days after exposure. Other 
manifestations are anorexia, weight loss and skin rashes. The majority of symptoms 
resolve themselves within 2 to 3 weeks, but some patients may suffer with arthralgias, 
myalgias, and fatigue that can last for months; hence the synonym, “desert 
rheumatism.”11 
  
Community Acquired Pneumonia is a common presentation at healthcare settings and is 
usually indistinguishable from bacterial or other causes of Pneumonia. Patients can have 
infiltrates, adenopathy or effusion on chest radiographs. In a study that evaluated patients 
presenting with symptoms of Community Acquired Pneumonia in Arizona, 29% of the 
patients were found to have Coccidioidomycosis.12 In the majority of patients, the 
infection is mild and resolves itself without specific antifungal treatment. Some patients 
may develop chronic pulmonary nodules or cavities that are asymptomatic or that cause 
symptoms such as chest pain, dyspnea, or hemoptysis.13 
 
In a few groups of patients, the infection is severe and causes diffuse pneumonia and 
respiratory failure leading to extrapulmonary dissemination. The immunocompromised, 
such as those dealing with HIV/AIDS, malignancy, organ transplant (solid organ and 




corticosteroid therapy, chemotherapy, or anti-TNF medications, are particularly at risk.10 
Fewer than 5% of the general population develops persistent pulmonary infection or 
disseminated Coccidioidomycosis.14 In a study of Coccidioidomycosis in patients on 
renal replacement therapy the rate of disseminated infection was 75% with a mortality 
rate of 63% for those receiving immunosuppressive therapy.15 Dissemination can affect 
any organ, but the most common sites are skin, soft tissues, bones, joints, and meninges.16  
 
DIAGNOSIS  
Laboratory tests available to diagnose Coccidioidomycosis include serologic, direct 
microscopy, histopathology, culture, Polymerase Chain Reaction (PCR), urine antigen, 
and skin testing. Serologic response to Coccidioidomycosis is the production of two types 
of antibodies, IgM and IgG. The IgM antibodies are seen early during the course of 
infection and wean off rapidly, whereas IgG antibodies are produced later and persist for 
much longer.17 The most commonly used tests for IgG are Enzyme Immunoassay (EIA), 
Immunodiffusion (ID) and Complement Fixation (CF); those for IgM are EIA and ID.18 
Both ID and EIA are reported as quantitative and/or qualitative, whereas CF is reported 
as titer. 
 
 EIA is considered the most sensitive test but is prone to false positives, particularly for 
IgM. Hence, it is recommended that ID testing, which is the most specific, be used to 
confirm a positive EIA.19, 20 Immunodiffusion (ID) tests for the presence of precipitin 
(IgM) or CF (IgG) antibodies and can be done both as qualitative and quantitative test. 




supports the diagnosis made by EIA/ID, helps assess the severity of the disease, and can 
be used to follow its course over time and measure its response to treatment.21 A low CF 
titer can be the result of a new infection or one from years ago. If the test results change 
on repeat measurement, it indicates a recent infection. The higher the titer, the more 
severe the disease and titers greater than 1:16 indicate the possibility of disseminated 
disease. In addition, the CF test is the primary serologic test to diagnose meningitis and 
its presence in cerebrospinal fluid (CSF) is diagnostic.22 
 
Since Coccidioides is not part of the normal flora of humans, identification of the 
organism in clinical specimens is considered the gold standard for diagnosis.23 Common 
specimens are sputum, tracheal aspirate, bronchoalveolar lavage (BAL), lung/pleural 
biopsy, blood, CSF or other body fluids and tissue biopsy. The organism can either be 
identified by direct microscopy or after growth in fungal cultures. Direct microscopy can 
also reveal spherules, which are diagnostic, although not definitive as seeing organism 
itself since spherules can be mistaken for other fungi or artifacts.24 Histopathology using 
special stains such as Grocott methenamine silver (GMS), Periodic acid Schiff (PAS) and 
Hematoxylin-eosin (H&E) is an important direct microscopy method.25 
 
Coccidioides are not very fastidious and grow on most any bacterial or fungal culture 
media. The commonly used fungal media are brain-heart infusion agar (BHI), Sabouraud 
dextrose agar (SDA), and potato dextrose agar (PDA).24 Once there is growth on the 
culture media, Coccidioides can be rapidly identified by a DNA probe test (AccuProbe) 




The test is highly sensitive and specific and takes less than 1 hour. In vitro susceptibility 
testing is then carried out to identify susceptibility to the common antifungal drugs. 
 
Culture can take days to weeks and cause delays in diagnosis and treatment. A Real-Time 
PCR assay has been developed that can detect Coccidioides directly in clinical 
specimens.27 It is highly sensitive and specific and has the potential to diagnose within 
hours; however, it is still not the standard diagnostic test. Another rapid way to diagnose 
Coccidioidomycosis is antigen testing. A Coccidioides Antigen Enzyme Immunoassay 
(EIA) was developed that detects urinary antigen and had sensitivity of 71% in cases of 
severe Coccidioidomycosis.28  
 
The cellular immunity to Coccidioidomycosis can be tested by Coccidioidin skin test, 
which is a delayed-type hypersensitivity reaction.29 Patients develop dermal reactivity to 
the infection that lasts a lifetime, therefore, a positive test is not always helpful to 
diagnose current illness unless the patient is known to have had a negative test in the past. 
However, it is an important epidemiological test to study prevalence geographically. 
 
TREATMENT 
Treatment of Coccidioidomycosis depends on the severity of infection and a patient’s risk 
factors for complications, such as immunosuppression or pregnancy. Patients with mild 
symptoms and no risk factors can be managed without antifungal drugs but need to be 
frequently monitored for worsening conditions and resolution. Although most patients 




Several drugs are used in practice both in inpatient and outpatient settings. Intravenous 
Amphotericin B is typically used for severe infections. Other available drugs are the 
antifungal Azoles, Ketoconazole, Fluconazole, Itraconazole, Voriconazole and 
Posaconazole. Sometimes in severe infections Amphotericin B is combined with an 
















Describe current epidemiology of Coccidioidomycosis in Missouri using state’s 
electronic surveillance database of reportable conditions.  
 
STUDY PERIOD 
Study was conducted for the period of 2004-2013. This study period included years when 
the complete Coccidioidomycosis surveillance data was available.  
 
STUDY POPULATION 
The study population included the entire Missouri state population during the study 




We conducted a retrospective review of communicable disease surveillance at the 
Missouri Department of Health & Senior Services (DHSS). Data was obtained from 




system for notifiable diseases. All cases that were “Confirmed” were included in the 
study. The study was done at the Missouri DHSS as a part of surveillance data 
evaluation. The study was approved by Institutional Review Board of Purdue University, 
West Lafayette, IN. 
 
Following variables were analyzed: Age, Sex, Race, Co-morbid conditions (HIV/AIDS, 
Cancer, Diabetes, Heart disease, Lung disease, Organ transplant, Immunosuppressive 
disease, and Immunosuppressive drugs), Residential address, Travel to endemic areas, 
Occupational risk, Serology (Immunodiffusion, Complement Fixation, Enzyme-linked 
immunoassay), Histopathology, Culture, Polymerase Chain Reaction (PCR), Urine 
antigen, and Skin testing. 
 
Cases were compared using their travel to endemic area status using above mentioned 
variables. 
 
CASE DEFINITION 31 
“Confirmed case” of Coccidioidomycosis in the study was based on the case definition 
consistent with the definition used by the CDC’s National Notifiable Diseases 






Infection may be asymptomatic or may produce an acute or chronic disease. Although the 
disease initially resembles an influenza-like or pneumonia-like febrile illness primarily 
involving the broncho-pulmonary system, dissemination can occur to multiple organ 
systems. An illness is typically characterized by one or more of the following: 
 Influenza-like signs and symptoms (e.g., fever, chest pain, cough, myalgia, 
arthralgia, and headache) 
 Pneumonia or other pulmonary lesion, diagnosed by chest radiograph 
 Erythema nodosum or erythema multiforme rash 
 Involvement of bones, joints, or skin by dissemination 
 Meningitis 
 Involvement of viscera and lymph nodes 
 
LABORATORY CRITERIA FOR DIAGNOSIS 
A confirmed case must meet at least one of the following laboratory criteria for 
diagnosis: 
 Cultural, histopathologic, or molecular evidence of presence 
of Coccidioides species, OR 
 Positive serologic test for coccidioidal antibodies in serum, cerebrospinal fluid, or 
other body fluids by: 
o Detection of coccidioidal immunoglobulin M (IgM) by immunodiffusion, 
enzyme immunoassay (EIA), latex agglutination, or tube precipitin, OR 
o Detection of coccidioidal immunoglobulin G (IgG) by immunodiffusion, 
EIA, or complement fixation, OR 
o Coccidioidal skin-test conversion from negative to positive after onset of 







A case that meets the clinical criteria and is laboratory confirmed. 
 
STATISTICAL METHODS 
All data was analyzed using R statistical software with significance defined as P < 0.05 
level. Poisson regression analysis was used to model Coccidioidomycosis trend over 
time. Shapiro test was used to determine if studied groups follow normal distribution.  
Mann-Whitney U test was used to compare groups with no normal distribution. 
Hypothesis tests for proportions was conducted to evaluate the difference between the 
proportions of patients with a specific symptom, proportion of patients with positive 


















CHAPTER 3. RESULTS 
 
There were a total of 93 reported cases during the years, 2004-2013. (Figure 3) Of these 
67 (72%) were male and 26 (28%) were female. The age distribution showed no cases 
less than 10 years, 1 case 10-19 years, 6 cases 20-29, 12 cases 30-39, 15 cases 40-49, 16 
cases 50-59, 21 cases 60-69 and 22 cases greater than or equal to 70 years. With regard to 
race, 50 (54%) were white, 7 were black, 1 was a Pacific Islander, 1 was Asian and the 






























              Age group (years) 










Male Female  10-19 20-29 30-39 40-49 50-59 60-69 > 70 White Black Pacific Islander Asian Unknown
2004 3 2 1 0 0 0 1 0 1 1 2 0 0 0 1
2005 1 1 0 0 1 0 0 0 0 0 0 0 0 0 1
2006 2 2 0 0 0 0 0 2 0 0 1 0 0 0 1
2007 9 8 1 0 1 1 2 2 2 1 5 1 0 0 3
2008 3 2 1 0 2 0 0 0 0 1 3 0 0 0 0
2009 11 6 5 0 0 1 1 5 1 3 9 0 0 1 1
2010 14 7 7 0 0 4 2 1 3 4 7 2 0 0 5
2011 18 17 1 0 1 3 3 2 3 6 8 1 1 0 8
2012 15 12 3 1 1 2 2 2 6 1 7 2 0 0 6
2013 17 10 7 0 0 1 4 2 5 5 8 1 0 0 8










































2004 3 0 0 3 0 0 0 0 0 0 0
2005 1 0 0 1 0 0 0 0 0 0 0
2006 2 1 0 1 0 0 0 0 0 0 0
2007 9 0 1 3 2 1 0 0 1 0 1
2008 3 0 0 2 0 1 0 0 0 0 0
2009 11 0 0 3 5 0 2 0 0 1 0
2010 14 2 1 5 4 0 1 0 0 0 1
2011 18 8 2 4 3 1 0 0 0 0 0
2012 15 3 0 7 0 0 2 0 1 2 0
2013 17 5 0 4 2 1 1 2 1 1 0

















Figure 8.  Mapping of Coccidioidomycosis cases by travel to endemic areas, MO, 2004-
2013 Red: not traveled to endemic, Blue: traveled, Green: unknown 
 
 
Clinical presentation of cases, for whom data was available (86/93), included: 2 cases 
with asymptomatic lung lesions, 14 (15%) with symptomatic lung lesions, 20 (22%) with 
flu-like illness, 4 with flu-like illness and skin lesions, 5 with Flu-like illness and night 
sweats, 2 with Flu-like illness and weight loss, 5 with hemoptysis, 21 (23 %) with 
Pneumonia, 2 with Arthritis/Arthralgia, 3 with headache/confusion, 3 with only skin 
lesions, 1 with Meningitis, 2 with Respiratory failure, 1 with sepsis, 1 presented with 











Table 3.  Clinical presentation of Coccidioidomycosis cases 
 
 
Patients were also diagnosed using several combinations of tests: 20 (22%) had 
Complement Fixation (CF), 15 (16%) had Immunodiffusion, 4 had CF and 
Immunodiffusion, 1 had CF and Culture, 1 had CF, Immunodiffusion and Culture, 1 had 
CF, PCR and Culture, 1 had CF and Histopathology, 1 had Histopathology, 9 had 
EIA/ELISA, 2 had EIA/ELISA and Immunodiffusion, 1 had EIA/ELISA and culture, 24 
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 TOTAL (%)
Total reported cases 3 1 2 9 3 11 14 18 15 17 93
Lung lesions, asymptomatic 0 0 0 0 0 0 0 0 2 0 2 (2%)
Lung lesions, symptomatic 0 0 0 0 1 1 4 2 3 3 14 (15%)
Flu like illness 2 0 1 1 1 3 4 3 3 2 20 (22%)
Flu like illness and skin lesions 0 0 0 0 0 1 1 0 0 2 4 (4%)
Flu like illness and night sweats 0 1 0 1 0 2 0 1 0 0 5 (5%)
Flu like illness and weight loss 0 0 1 0 0 1 0 0 0 0 2 (2%)
Hemoptysis 0 0 0 1 0 1 0 2 0 1 5 (%)
Pneumonia 0 0 0 2 0 1 1 7 3 7 21 (23%)
Arthritis/Arthralgia 0 0 0 0 0 1 1 0 0 0 2 (2%)
Headache/Confusion 0 0 0 1 0 0 0 0 1 1 3 (3%)
Skin lesions 0 0 0 1 0 0 1 0 1 0 3 (3%)
Meningitis 0 0 0 0 0 0 0 1 0 0 1 (1%)
Respiratory failure 0 0 0 0 1 0 0 0 0 1 2 (2%)
Sepsis 0 0 0 0 0 0 0 0 1 0 1 (1%)
Disseminated 0 0 0 0 0 0 0 0 1 0 1 (1%)




(2 %) had Culture, 1 had EIA/ELISA, Immunodiffusion and Culture, 3 had PCR and 9 
(10%) had unknown serology. (Table 4) 
 
Table 4.  Laboratory diagnosis of Coccidioidomycosis cases part 1 
 
 
Table 5.  Laboratory diagnosis of Coccidioidomycosis cases part 2 
 
 
Out of 93 cases, 51 (55%) patients had the exact date of symptom onset documented. 
Time to diagnosis ranged from 3 to 304 days with a median of 25 days. A total of 43 













2004 3 0 0 0 0 0 0 0 0
2005 1 0 0 0 0 0 0 0 0
2006 2 1 0 0 0 0 0 0 0
2007 9 2 0 0 0 0 0 0 1
2008 3 0 0 0 0 0 0 0 0
2009 11 1 2 0 0 1 0 1 0
2010 14 1 4 0 0 0 0 0 0
2011 18 6 3 1 0 0 0 0 0
2012 15 3 2 1 1 0 0 0 0
2013 17 6 4 2 0 0 1 0 0














2004 3 0 0 0 2 0 0 1
2005 1 0 0 0 0 0 1 0
2006 2 0 0 0 1 0 0 0
2007 9 1 0 0 5 0 0 0
2008 3 0 0 0 0 0 3 0
2009 11 0 0 1 5 0 0 0
2010 14 1 1 0 3 0 2 2
2011 18 2 0 0 4 0 2 0
2012 15 5 1 0 1 0 1 0
2013 17 0 0 0 3 1 0 0




(46%) patients required hospitalization and 5 of these were admitted to an ICU. With 
regard to available documentation on antifungal treatment, 29 patients received 
antifungal treatment and of these, 14 had outpatient therapy and 15 were inpatients. 
Fluconazole was the most used antifungal in 19 patients. 4 patients received Itraconazole, 
2 received Fluconazole and Itraconazole, 1 received Voriconazole, 2 received 
Amphotericin B and 1 received Amphotericin B and Itraconazole. Of the 93 total cases, 8 
died: 3 attributed to Coccidioidomycosis, 3 from other illnesses, and the cause of death in 
the remaining 2 was not known. Review of history of previous infection showed that 10 
patients had a prior history of Coccidioidomycosis and the current infection was a 
recurrence. 
 
On reviewing the travel history to endemic regions (States-CA, AZ, UT, NM, NV and 
TX. Countries-Mexico, South America), 45 (48%) had travel history, 24 (26%) had no 
travel history and the travel history of the remaining 24 (26%) was unknown. Among the 
45 cases with travel history, 19 (20%) had recent travel (defined as development of 
symptoms while in endemic area or within 21 days of returning from travel to an endemic 
area), 20 had remote travel or history of residence in endemic regions, and the travel 
timeline of 6 cases was not known. There were 17 (18%) cases that were 
immunocompromised and 8 of these had travel history to endemic regions.  
 
Of the 69 patients with known travel history, 45 had history of travel and 24 had no travel 





Table 6.  Characteristics of Coccidioidomycosis cases by travel history 






Age, years, median 63 67 50
Male sex 32/45 (71) 14/19 (74) 20/24 (83)
Race
White 28/45 (62) 13/19 (68)  10/24 (42)
Black  4/45 (9) 0/19 (0)  1/24 (4)
Pacific Islander 0/45 (0) 0/19 (0)  1/24 (4)
Asian 0/45 (0) 0/19 (0)  1/24 (4)
Unknown Race 13/45 (29)  6/45 (13)  11/24 (46)
Presentation
Asymptomatic lung lesions 0/45 (0) 0/19 (0)  1/24 (4)
Symptomatic lung lesions  7/45 (16)  2/19 (11)  5/24 (21)
Flu-like illness 13/45 (29)  7/19 (37)  10/24 (42)
Pneumonia  10/45 (22)  7/19 (37)  5/24 (21)
Hemoptysis  4/45 (9)  1/19 (5)  1/24 (4)
Arthralgia/Arthritis  2/45 (4)  1/19 (5) 0/24 (0)
Headache/Confusion  2/45 (4) 0/19 (0) 0/24 (0)
Skin lesions  2/45 (4) 0/19 (0) 0/24 (0)
Meningitis  1/45 (2) 0/19 (0) 0/24 (0)
Sepsis 0/45 (0) 0/19 (0)  1/24 (4)
Respiratory failure  1/45 (2) 0/19 (0) 0/24 (0)
Disseminated  1/45 (2) 0/19 (0) 0/24 (0)
Unknown  2/45 (4)  1/19 (5)  1/24 (4)
Days, symptoms to diagnosis, 
Median (range) 52 (3-304) 55 (6-123) 17 (6-108)
Type of test
CF  10/45 (22)  4/19 (21)  7/24 (29)
Immunodiffusion  9/45 (20)  2/19 (11)  9/24 (38)
EIA/ELISA  6/45 (13)  3/19 (16)  5/24 (21)
Culture 18/45 (40)  7/19 (37)  4/24 (17)
PCR  3/45 (7)  3/19 (16) 0/24 (0)
Histopathology  2/45 (4) 0/19 (0) 0/24 (0)
Unknown serology  5/45 (11)  2/19 (11)  3/24 (13)
Hospitalization 27/45 (60) 11/19 (58)  9/24 (38)
All data are n/total (%). 





Poisson regression analysis was used for the Coccidioidomycosis trend analysis during 
2004-2013. By applying the Poisson regression model, we assume that the disease 
occurrence is rare and cases are independent; in other words, occurrence of 
Coccidioidomycosis does not increase or decrease the likelihood of other occurrences.  
Model   (where x is the year) was significant at p<0.001 level. 
 
 
Figure 9. Poisson Regression model of Coccidioidomycosis incidence in Missouri (rate 






According to Hastie and Pregibon, for models with known dispersion (e.g., binomial and 
Poisson fits), the chi-square test is most appropriate, and for those with dispersion 
estimated by moments (e.g., gaussian, quasibinomial and quasipoisson fits) the F test is 
most appropriate.32 Thus, analysis of variance was employed using chi-square to evaluate 
the Poisson regression model. 
 
The patients with known travel history were categorized into three groups: 1) patients 
who have “not traveled” to the endemic areas, 2) patients who have “traveled” to 
endemic areas at any time and 3) patients who have “recently traveled” to such areas. 
According to the distributions (Figure 10), the age of patients who have “traveled” (either 
recently or not) is skewed to the left while the patients who have “not traveled” are 
skewed to the right. We used Shapiro test to analyze the age distribution data. The p-
value for the “not traveled”, “traveled”, and “recently traveled” groups are 0.659, 0.052, 
and 0.002, respectively. The test result shows that “not traveled” groups are following a 
normal distribution while “recently traveled” are not, and the p-value for the “traveled” 






Figure 10.  Probability density function of patient ages for “Traveled”, “Not Traveled”, 
and “Recently Traveled” groups 
 
The p-value of the nonparametric Kruskal-Wallis test is 0.02603 that shows that at least 
distribution of one pair is not identical. Since the distributions are not normal, Pairwise 
Mann-Whitney-Wilcoxon tests are used to check whether the distributions of each pair 
are identical. We also applied Mood’s nonparametric test to assess whether the median of 
each groups are identical. Test results (Table 7) reveal that the median of “not traveled” 
vs. “traveled” and “not traveled” vs. “recently traveled” are not identical. In addition not 
traveled patients and recently traveled patients do not follow identical age distribution but 









Table 7. Age comparisons of Not Traveled, Traveled and Recently Traveled groups 
 
 
The second variable analyzed between traveled, not traveled, and recently traveled is the 
days to diagnosis. Figure 11 shows the days to diagnosis distribution of each group. 
Kolmogrov-Smirnov test is applied to check whether the data follows exponential 
distribution. P-values for traveled, not traveled, and recently traveled patients are 0.2819, 
0.2923, and 0.2982, respectively. Thus, the study finds that days to diagnosis variable of 
each group follows exponential distribution. Table 8 shows the mean and median 
information for each group. 
 
Comparisons Mood's Median Test
w p-value p-value









Figure 11.  Probability density function of patient day to diagnosis for "Traveled", "Not 
Traveled", and "Recently Traveled" groups 
 
Table 8. Mean and median days to diagnosis for “Traveled”,” Not Traveled”, and 





Since the time to diagnosis follows exponential distribution, we use Mann-Whitney-
Wilcoxon U tests to check if days to diagnosis variable of different groups of patients 
follows an identical distribution. According to the test results, there is not a strong 
difference between the days to diagnosis distribution of not traveled and traveled patients, 
Mean Median









however there is a difference between the days to diagnosis distribution of not traveled 
and recently traveled patients. (Table 9) 
 





In addition to age and days to diagnosis variables, we tested whether diagnosis symptoms 
are different between “traveled” vs. “not traveled” and “not traveled” vs. recently 
traveled” patients.  According to the F-test results (Table 10), the symptoms to diagnosis 











Not Traveled Vs. 
Traveled 221 0.0912
Not Traveled Vs.
Recently Traveled 53.5 0.03931




Table 10. Patient proportions with a specific symptom and test results for comparing the 
proportions of “Traveled vs. Not Traveled” group of patients and proportions of “Not 





Testing results are also compared between “traveled vs. not traveled” and “not traveled 
vs. recently traveled” patients (Table 11). According to the test results, the proportion of 
positive Culture + PCR results is larger for “traveled” (and recently traveled) patients 
than for “not traveled” ones. The proportion of other positive results do not significantly 











0.163 0.217 0.8312 0.217 0.111 0.6317
0.302 0.435 0.421 0.435 0.389 1
0.232 0.217 1 0.217 0.389 0.3943
0.093 0.043 0.8129 0.043 0.055 1Hemoptysis









Table 11. Hypothesis test results for comparing proportion of patients whose specimens 




We also assessed the hospitalization variable between “traveled and not traveled” or “not 
traveled and recently traveled” groups of patients. The p-values of the comparisons are 
0.1129 and 0.3103, respectively. Thus, the results show that the hospitalization 
proportions do not significantly change between “Traveled and Not Traveled” or “Not 
Traveled and Recently Traveled” groups of patients.







CF 0.25 0.333 0.6971 0.333 0.235 0.762
Immunodiffusion 0.225 0.428 0.1735 0.428 0.118 0.08157
EIA/ELISA 0.15 0.238 0.6172 0.238 0.176 0.9496
Culture + PCR 0.525 0.19 0.024 0.19 0.588 0.02858




CHAPTER 4. DISCUSSION 
 
Our study found a statistically significant increase in the incidence of 
Coccidioidomycosis in Missouri with rate going from 0.05 per 100,000 population in 
2004 to 0.28 per 100,000 in 2013. Our findings are consistent with the national trend of 
increasing incidence of Coccidioidomycosis (from 2,271 cases in 1998 to 17,802 cases in 
2012) that includes both endemic and non-endemic states.6 Mapping of cases with and 
without history of travel to the endemic areas outside the state revealed that cases were 
occurring in all regions of Missouri. Since the study cases were distributed throughout the 
state, endemic foci of Coccidioidomycosis in Missouri seem unlikely. 
 
One explanation for the increase in reported cases in Missouri could be the fact that it 
became reportable in 2003. There could be increased awareness in healthcare providers 
and the public leading to more testing. An increase in Coccidioidomycosis incidence has 
been observed in Arizona after it became reportable in 1997. The incidence increased 
from 21/100,000 in 1997 to 91/100,000 in 2006.33  
 
For the resident of a non-endemic area, travel to an endemic state is a major risk factor 
for acquiring Coccidioidomycosis. In our study, those with no travel history were 




differences regarding the most common clinical symptoms, rate of hospitalization, 
treatment with antifungals, or death. Those with history of travel were significantly more 
likely to be diagnosed based on positive culture and/or PCR testing compared to those 
who did not travel, who were more likely to be diagnosed with serological tests. Since the 
culture and PCR are more accurate tests for diagnosing recent Coccidioidomycosis 
infection compared to serological tests, it is difficult to say with certainty whether all 
cases with no travel history were truly experiencing this infection. 
  
Current Coccidioidomycosis surveillance case definition makes no distinction between 
those with travel or residence in the endemic area and those without any of it, although 
performance of the diagnostic tests in detecting true cases is variable. Since people living 
in non-endemic areas have a much lower risk of having Coccidioidomycosis, a different, 
more stringent requirement for laboratory diagnosis of such cases seems prudent. It has 
been shown that laboratory tests may falsely categorize patients into Coccidioidomycosis 
cases since false positive tests are common when diagnosis is confirmed solely based on 
positive serology.20 Also, it was not clear in some  cases if the positive antibody test was 
IGG or IGM, and what was the titer for the Complement Fixation (CF) test. 
 
Accurate history of travel to endemic areas is very important. In our study, the travel 
history of 26% of cases was unknown. It’s possible that several of these patients traveled 
to endemic areas. Also, sometimes people may dismiss brief travels as insignificant and 
not report it but studies have shown that even changing planes or driving through an 




risk factor for fungal diseases, including Coccidioidomycosis. 34 In our study 17 % of 
patients were immunocompromised and some patients’ immunocompromised state, 
particularly diabetes, could have been missed due to incomplete documentation of past 
medical history.  
 
The main limitation of our study is that the retrospective analysis was conducted on 
routine surveillance data, and no medical chart review or direct patient interviews were 
conducted. The surveillance data was incomplete for some cases in respect of 
demographics, travel history, medical history, clinical presentation, diagnosis, treatment, 
and follow up. The race of cases was missing in 37 % of cases, while it is known that 
African-Americans are at increased risk for severe infections and hospitalizations. In a 
study looking into hospitalizations in Arizona and California, the hospitalization rate for 
blacks in Arizona was 12-fold higher than the rate for whites.35  
 
For future research, the data collection and documentation in the surveillance database 
should be more comprehensive. Demographics such as, race, occupation, travel history, 
and comorbid conditions are important in identifying at risk patients and need to be 
specifically addressed. It is important to document the exact diagnostic tests used for 
serology, whether it is IgG or IgM, and the exact titer for CF. Follow up of patients after 
the initial reporting by a lab or hospital is crucial to make sure no alternative diagnoses 





Also, Soil analysis for Coccidioides spores in various parts of Missouri can be extremely 
helpful to characterize the changing endemicity.  We were unable to find any literature 
available to us documenting the presence of Coccidioides spores in Missouri. A cluster 
analysis of a larger sample of Coccidioidomycosis cases using SAT scan could be needed 
to provide a more accurate answer whether endemicity exists in Missouri. If further 
surveillance reveals more Coccidioidomycosis cases and/or disease clusters among 
Missouri residents without history of travel to endemic areas, an environmental study 
would also be warranted.  
 
In conclusion, our study demonstrated significant increase in the incidence of 
Coccidioidomycosis in Missouri. Majority of cases are related to travel to endemic areas. 
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